Table 4.
Experimental Compounds In Phases 1 to 3 of Clinical Development
| Unapproved Antiepileptic Agents | Structural Relationship |
|---|---|
| Fluorofelbamate | Felbamate |
| Brivaracetam (Rikelta) | Levetiracetam |
| Seletracetam | Levetiracetam |
| Valrocemide | Valproic acid |
| Valnoctamide | Valproic acid |
| Propyl isopropyl acetamide | Valproic acid |
| Isovaleramide | Valproic acid |
| Carisbamate | Carbamate |
| Ganaxolone | Allopregnanolone |
| Talampanel | Benzodiazepine derivative |
| ICA-27243 | Retigabine |
| JZP-4 | Lamotrigine |
| Licarbazepine | Oxcarbazepine |
| ELB139 | Benzodiazepine receptor agonist |
| T2000 | Phenobarbital |
| XP13512 | Gabapentin |
| Tonabersat | Benzopyran |
| YKP-3089 | New chemical unrelated to others |
| NAX5055 | Galanin analogue |
| NPS1776 | Broad-spectrum antiseizure butanamide |
| ELB139 | Benzodiazepine agonist |
| ICA27243 | Selective KCNQ2/Q3 activators with anticonvulsant-like activity |
| Paxiline | Preclinical development only |
| NS1209 | Enhance GABAergic transmission |
| 2-deoxy-d-glucose | Antiseizure activity |